Intercept Pharmaceuticals, Inc. (ICPT) Financial Metrics
This dashboard provides comprehensive financial metrics and analysis to help evaluate Intercept Pharmaceuticals, Inc.'s investment potential. View key valuation ratios, profitability metrics, growth indicators, and historical trends to make informed investment decisions.
Financial Metrics Score
Valuation Metrics
Sector benchmarks: Industrials
P/E Ratio
3.63
Strong
WeakModerateStrong
P/B Ratio
4.49
Strong
WeakModerateStrong
Earnings Yield
27.53%
Strong
WeakModerateStrong
Profitability Health
2022Return on Equity
123.74%
Strong
WeakModerateStrong
Operating Margin
-23.88%
Weak
WeakModerateStrong
Net Profit Margin
40.31%
Strong
WeakModerateStrong
Growth Indicators
2022Revenue Growth
-21.39%
Weak
WeakModerateStrong
Net Income Growth
179.42%
Strong
WeakModerateStrong
EPS Growth
174.95%
Strong
WeakModerateStrong
Efficiency & Liquidity
2022Current Ratio
2.35
Strong
WeakModerateStrong
Quick Ratio
2.35
Strong
WeakModerateStrong
Asset Turnover
0.52x
Moderate
WeakModerateStrong
Inventory Turnover
984000.00x
Strong
WeakModerateStrong
Cash Flow & Resilience
Core fortress metrics for cash-rich balance sheets in high-inflation / tech-volatility regimes
Free Cash Flow Yield
-6.54%
Weak
WeakModerateStrong
EV / Free Cash Flow
-25.62x
Strong
WeakModerateStrong
Net Debt / EBITDA
-4.57x
Strong
WeakModerateStrong
Interest Burden (EBT / EBIT)
2.563
Strong
WeakModerateStrong
Return on Invested Capital
10.37%
Weak
WeakModerateStrong
Cash Conversion Cycle
-5245.57 days
Strong
WeakModerateStrong
Fortress screener guardrails
2/4 passing
- FCF Yield > 3%
- Net Debt / EBITDA < 1.5x
- ROIC > 20%
- Cash Conversion Cycle < 0 days
Financial Statements
Want to see the complete financial picture? View detailed financial statements including income statements, balance sheets, and cash flow statements for ICPT.
View Financial Statements